COVID-19 Vaccination Quick Links

Current as of January 7, 2022

Numerous tools and resources are available to inform the COVID-19 vaccination efforts of healthcare providers, including ASPR TRACIE’s technical assistance response focused on the healthcare facility response during the first six months of the vaccine roll out. ASPR TRACIE created this list to assist clinicians in quickly finding the most relevant and current information about COVID-19 vaccines available in the United States, their intended populations, recommendations for their use, effectiveness and safety issues, potential adverse events to be aware of, the effects of SARS-CoV-2 variants on the vaccinated, and resources to help communicate with patients. Additional resources are also listed to access more detailed information.

Vaccines Available in the U.S.

**Pfizer-BioNTech**

FDA approved (COMIRNATY)
- 2 dose primary series in individuals 16 years of age and older

FDA Emergency Use Authorization (EUA)
- 2 dose primary series in individuals 5-15 years of age
  - Dose is lower for those ages 5-11
- 3rd dose in primary series for certain immunocompromised individuals 5 years of age and older
- Booster dose at least 5 months after primary series for those ages 12 and older, including moderately or severely immunocompromised people ages 18 and older

**Moderna**

FDA EUA
- 2 dose primary series in individuals 18 years of age and older
- 3rd dose in primary series for certain immunocompromised individuals 18 years of age and older
- Booster dose at least 5 months after primary series for those ages 18 and older, including those who are moderately or severely immunocompromised

**Johnson & Johnson/Janssen**

FDA EUA
- 1 dose in individuals 18 years of age and older
- Booster dose at least 2 months after primary dose for those ages 18 and older, including those who are moderately or severely immunocompromised

FDA authorized heterologous, or mix-and-match, booster doses using any authorized vaccine. The timing of the booster dose and eligible population are based on the vaccine used for the primary series.

CDC preferentially recommends use of mRNA vaccines due to the rare but noted risk of thrombosis with thrombocytopenia syndrome associated with the Johnson & Johnson/Janssen vaccine.
# Recommendations

Advisory Committee on Immunization Practices COVID-19 Vaccine Recommendations

<table>
<thead>
<tr>
<th>SARS-CoV-2 Variants</th>
<th>Potential Adverse Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Variants of the Virus</strong></td>
<td><strong>Common Side Effects</strong></td>
</tr>
<tr>
<td><strong>Effectiveness</strong></td>
<td><strong>Anaphylaxis</strong></td>
</tr>
<tr>
<td>COVID-19 Vaccine Effectiveness</td>
<td>Guillain-Barre Syndrome</td>
</tr>
<tr>
<td><strong>Safety</strong></td>
<td>Myocarditis/Pericarditis</td>
</tr>
<tr>
<td>Ensuring COVID-19 Vaccine Safety in the U.S.</td>
<td>Thrombosis with Thrombocytopenia</td>
</tr>
</tbody>
</table>

## Communicating with Patients

- Be a COVID-19 Vaccine Champion Webinar
- Building Confidence in COVID-19 Vaccines
- Communication Resources for COVID-19 Vaccines
- Vaccines
- COVID-19 Vaccine Education

- COVID-19 Vaccine for Children
- Immunization Communications Resource Portal
- Vaccine Communications Tips
- Vaccine Recipient Education

## Additional Resources

- ASPR TRACIE: [COVID-19 Vaccine Resources Collection](#)
- CDC: [Vaccines for COVID-19](#)
- FDA: [COVID-19 Vaccines](#)
- NIH: [COVID-19 Vaccines](#)